<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fesoterodine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06702</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06702/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06702/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06702.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06702.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06702.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06702.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06702.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06702">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>FESO</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Fesoterodine Fumarate </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000085/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000085/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: MWHXMIASLKXGBU-RNCYCKTQSA-N</li>
              <li>Monoisotopic Mass: 527.288302671</li>
              <li>Average Mass: 527.649</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000085">DBSALT000085</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Toviaz</td><td>Pfizer </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/muscarinic-antagonists">Muscarinic Antagonists</a></li>
<li><a href="/mesh/anti-incontinence-agents">Anti-Incontinence Agents</a></li>
<li><a href="/mesh/antispasmodics">Antispasmodics</a></li>
<li><a href="/mesh/muscle-relaxants-genitourinary">Muscle Relaxants, Genitourinary</a></li></ul></td></tr><tr><th>CAS number</th><td>286930-03-8</td></tr><tr><th>Weight</th><td>Average: 411.5769<br>Monoisotopic: 411.277344055</td></tr><tr><th>Chemical Formula</th><td>C<sub>26</sub>H<sub>37</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>DCCSDBARQIPTGU-HSZRJFAPSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Diphenylmethanes</td></tr><tr><th>Direct parent</th><td>Diphenylmethanes</td></tr><tr><th>Alternative parents</th><td>Phenylpropylamines; Phenol Esters; Phenol Ethers; Alkyl Aryl Ethers; Tertiary Amines; Carboxylic Acid Esters; Enolates; Primary Alcohols; Polyamines</td></tr><tr><th>Substituents</th><td>phenol ester; phenylpropylamine; phenol ether; alkyl aryl ether; carboxylic acid ester; tertiary amine; primary alcohol; enolate; carboxylic acid derivative; polyamine; ether; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).</td></tr><tr><th>Pharmacodynamics</th><td>Fesoterodine is a prodrug. In-vivo it is broken down into its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), by plasma esterases. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. Therefore, acting as a competitive muscarinic receptor antagonist, fesoterodine ultimately acts to decrease the detrusor pressure by its muscarinic antagonism, thereby decreasing bladder contraction and consequently, the urge to urinate.</td></tr><tr><th>Mechanism of action</th><td>Fesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.</td></tr><tr><th>Absorption</th><td>Tmax (5-HMT): 5 hours post-adminitration of fesoterodine. 
AUC (0,&#8734;)= 49.5 ng&#183;h/ ml  
Bioavailability, 5-HMT = 52% </td></tr><tr><th>Volume of distribution</th><td><p>IV, 5-<span class="caps">HMT</span>: 169 L</p></td></tr><tr><th>Protein binding</th><td>5-HMT: 50% to albumin and alpha1-acid glycoprotein </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolized by ubiquitous, nonspecific esterases to transform fesoterodine into 5-HMT
Extensive metabolism via CYP2D6 and CYP3A4 into inactive metabolites </p></td></tr><tr><th>Route of elimination</th><td>Renal: 70% of fesoterodine was recovered in urine as 5-HMT; 35% carboxy metabolite; 18% carboxy-N-desisopropylmetabolite, and 1% N-desisopropyl metabolite 
Fecal: 7% 
Hepatic: fesoterodine elimination via CYP2D6 and CYP3A4</td></tr><tr><th>Half life</th><td>7-8 hours for the active metabolite 5-hydroxymethyl tolterodine </td></tr><tr><th>Clearance</th><td><p>5-<span class="caps">HMT</span>, healthy subjects: 14.4 L/h <br>
5-<span class="caps">HMT</span> is also secreted into the nephron.</p></td></tr><tr><th>Toxicity</th><td>Rat, Oral, LD50: ~ 681 mg/kg
Mouse, Oral, LD50: ~ 316 mg/kg 
Rat, Intravenous, NOAEL: 10 mg/kg
Mouse, Intravenous, NOAEL: 10 mg/kg</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9535</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.5648</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7699</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5268</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5556</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.625</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6025</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6853</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.5151</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5939</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6306</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7227</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.6255</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7334</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5718</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6144</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.646
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7213
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9385
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4003 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9196
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5602
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pfizer inc</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>4 mg </td></tr><tr><td>Tablet</td><td>Oral</td><td>8 mg </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine. Avoid fesoterodine doses greater than 4mg daily in patients who are also receiving strong CYP3A4 inhibitors. </td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole is a moderate CYP3A4 inhibitor thus reducing clearance. Monitor for adverse effects when using concomitant therapy with fesoterodine. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole is a potent CYP3A4 inhibitor thus reducing clearance. Avoid concomitant use with fesoterodine. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with or without food.</li></ul></td></tr></tbody></table>